ArticleNature biotechnology2019
Targeted transcriptional modulation with type I CRISPR-Cas systems in human cells.
Article in Nature biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- An Overview of Programmable Epigenetic Editing Based on CRISPR Tools for Gene Expression Regulation.Methods in molecular biology (Clifton, N.J.) · 2027Review
- Engineered targeted enhancement of translation in mammalian cell.BMC biology · 2026Article
- CRISPR-Cas3-based editing for targeted deletions in a mouse model of transthyretin amyloidosis.Nature biotechnology · 2026Article
- Single-molecule live-cell RNA imaging with CRISPR-Csm.Nature biotechnology · 2025Article
- Versatile and efficient mammalian genome editing with Type I-C CRISPR System of Desulfovibrio vulgaris.Science China. Life sciences · 2024Article
- Engineered minimal type I CRISPR-Cas system for transcriptional activation and base editing in human cells.Nature communications · 2024Article
- Natural and Engineered Guide RNA-Directed Transposition with CRISPR-Associated Tn7-Like Transposons.Annual review of biochemistry · 2024Review
- Single-molecule live-cell RNA imaging with CRISPR-Csm.bioRxiv : the preprint server for biology · 2024Article
- AlPaCas: allele-specific CRISPR gene editing through a protospacer-adjacent-motif (PAM) approach.Nucleic acids research · 2024Article
- Exploiting activation and inactivation mechanisms in type I-C CRISPR-Cas3 for genome-editing applications.Molecular cell · 2024Article
- Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases.Nature biotechnology · 2024Article
- Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox.Biochemistry · 2023Review
- Compact engineered human mechanosensitive transactivation modules enable potent and versatile synthetic transcriptional control.Nature methods · 2023Article
- Targeted large fragment deletion in plants using paired crRNAs with type I CRISPR system.Plant biotechnology journal · 2023Article
- Precise transcript targeting by CRISPR-Csm complexes.Nature biotechnology · 2023Article
- Genome-scale CRISPRi screening: A powerful tool in engineering microbiology.Engineering microbiology · 2023Review
- Repurposing the atypical type I-G CRISPR system for bacterial genome engineering.Microbiology (Reading, England) · 2023Article
- A Cas3-base editing tool for targetable in vivo mutagenesis.Nature communications · 2023Article
- Targeted DNA integration in human cells without double-strand breaks using CRISPR RNA-guided transposases.bioRxiv : the preprint server for biology · 2023Article
- Optimization of CRISPR-Cas system for clinical cancer therapy.Bioengineering & translational medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Class 2 CRISPR-Cas systems, such as Cas9 and Cas12, have been widely used to target DNA sequences in eukaryotic genomes. However, class 1 CRISPR-Cas systems, which represent about 90% of all CRISPR systems in nature, remain largely unexplored for genome engineering applications. Here, we show that class 1 CRISPR-Cas systems can be expressed in mammalian cells and used for DNA targeting and transcriptional control. We repurpose type I variants of class 1 CRISPR-Cas systems from Escherichia coli and Listeria monocytogenes, which target DNA via a multi-component RNA-guided complex termed Cascade. We validate Cascade expression, complex formation and nuclear localization in human cells, and demonstrate programmable CRISPR RNA (crRNA)-mediated targeting of specific loci in the human genome. By tethering activation and repression domains to Cascade, we modulate the expression of targeted endogenous genes in human cells. This study demonstrates the use of Cascade as a CRISPR-based technology for targeted eukaryotic gene regulation, highlighting class 1 CRISPR-Cas systems for further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.